← 產業報告目錄

Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-04-17頁數 371報告編號 BT9352

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes. The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period. In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time—making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market. Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period. Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings. The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period. The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region’s fastest growth during the forecast period. The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1—44%, Tier 2—32%, and Tier 3—24% • By Designation: (Managers)—45%, (CXOs, Directors)—30%, and (Executives)—25% • By Region: North America—40%, Europe—25%, Asia-Pacific—20%, Rest of the World—15% List of Companies Profiled in the Report: • Illumina, Inc. (US) • Thermo Fisher Scientific Inc. (US) • PacBio (US) • Oxford Nanopore Technologies PLC (UK) • 10X Genomics (US) • QIAGEN (Netherlands) • Agilent Technologies (US) • Danaher Corporation (US) • Takara Bio Inc. (Japan) • Adaptive Biotechnologies (US) • BGI Group (China) • Tecan Trading AG (Switzerland) • Azenta US Inc. (US) • Personalis, Inc. (US) • Creative Biolabs (US) • Celemics, Inc. (South Korea) • CellCarta (Canada) • iRepertoire, Inc. (US) • New England Biolabs (US) • Cerba Research (Belgium) • CeGat GmbH (Germany) • Element Biosciences (US) • Seqalis (Belgium) • Synbio Technologies (China) • MedGenome (US) • Enpicom (Netherlands) Research Coverage: This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product–end user, service–end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem. Reasons to Buy this Report : The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market. • Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market • Market Development: Comprehensive information about lucrative markets – the report analyses the immune repertoire sequencing market across varied regions. • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.
目錄 Table of Contents
1 INTRODUCTION 38 1.1 STUDY OBJECTIVES 38 1.2 MARKET DEFINITION 38 1.3 STUDY SCOPE 39 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD 39 1.3.2 INCLUSIONS & EXCLUSIONS 40 1.3.3 YEARS CONSIDERED 41 1.3.4 CURRENCY CONSIDERED 41 1.4 STAKEHOLDERS 41 2 RESEARCH METHODOLOGY 42 2.1 RESEARCH DATA 42 2.1.1 SECONDARY DATA 43 2.1.1.1 Key objectives of secondary research 43 2.1.2 PRIMARY DATA 43 2.1.2.1 Breakdown of primaries 44 2.1.2.2 Key objectives of primary research 44 2.2 MARKET ESTIMATION METHODOLOGY 45 2.2.1 GLOBAL MARKET ESTIMATION 45 2.2.1.1 Bottom-up approach 45 2.2.1.2 Insights from primary experts 48 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 48 2.3 MARKET GROWTH RATE PROJECTION 49 2.4 DATA TRIANGULATION 51 2.5 STUDY ASSUMPTIONS 52 2.6 RESEARCH LIMITATIONS 53 2.7 RISK ANALYSIS 53 3 EXECUTIVE SUMMARY 54 4 PREMIUM INSIGHTS 59 4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW 59 4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT AND COUNTRY 60 4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030 60 4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025 61 4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 61 5 MARKET OVERVIEW 62 5.1 INTRODUCTION 62 5.2 MARKET DYNAMICS 62 5.2.1 DRIVERS 63 5.2.1.1 Increasing technological advancements 63 5.2.1.2 Growing focus on personalized/precision medicines 64 5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring 64 5.2.1.4 Increasing applications in autoimmune disease research 65 5.2.1.5 Rising focus on cancer immunotherapy research 65 5.2.2 RESTRAINTS 66 5.2.2.1 Need for high capital investments 66 5.2.2.2 Limited clinical adoption and validation 66 5.2.3 OPPORTUNITIES 66 5.2.3.1 Integration of AI and ML into immune repertoire sequencing 66 5.2.3.2 Increasing applications in vaccine development 67 5.2.4 CHALLENGES 67 5.2.4.1 Variations in regulatory frameworks and international trade dynamics 67 5.2.4.2 Lack of workflow and data standardization 68 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68 5.4 PRICING ANALYSIS 69 5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 69 5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 71 5.5 SUPPLY CHAIN ANALYSIS 72 5.6 VALUE CHAIN ANALYSIS 73 5.7 ECOSYSTEM ANALYSIS 75 5.7.1 ROLE IN ECOSYSTEM 76 5.7.1.1 Product providers 76 5.7.1.2 Service providers 76 5.7.1.3 End users 77 5.7.1.4 Regulatory bodies 77 5.8 TECHNOLOGY ANALYSIS 78 5.8.1 KEY TECHNOLOGIES 78 5.8.1.1 High-throughput sequencing 78 5.8.1.2 Nanopore sequencing 78 5.8.1.3 Single-molecule real-time (SMRT) sequencing 78 5.8.2 COMPLEMENTARY TECHNOLOGIES 79 5.8.2.1 Bioinformatics and data analysis platforms 79 5.8.2.2 Multiplex PCR 79 5.8.2.3 5’RACE 79 5.8.3 ADJACENT TECHNOLOGIES 80 5.8.3.1 Multi-omics integration 80 5.8.3.2 Spatial genomics and transcriptomics 80 5.8.3.3 Single-cell sequencing technologies 80 5.9 PATENT ANALYSIS 81 5.10 TRADE DATA ANALYSIS 82 5.10.1 IMPORT DATA FOR HS CODE 3822, 2020−2024 82 5.10.2 EXPORT DATA FOR HS CODE 3822, 2020−2024 84 5.11 KEY CONFERENCES & EVENTS, 2025–2026 85 5.12 REGULATORY ANALYSIS 86 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 5.12.2 REGULATORY FRAMEWORK 88 5.12.2.1 North America 88 5.12.2.1.1 US 88 5.12.2.1.2 Canada 88 5.12.2.2 Europe 89 5.12.2.2.1 UK 89 5.12.2.3 Asia Pacific 89 5.12.2.3.1 China 89 5.12.2.3.2 Japan 90 5.12.2.3.3 South Korea 90 5.12.2.3.4 Australia 91 5.12.2.3.5 India 91 5.12.2.3.6 Rest of Asia Pacific 91 5.13 PORTER’S FIVE FORCES ANALYSIS 92 5.13.1 THREAT OF NEW ENTRANTS 93 5.13.2 THREAT OF SUBSTITUTES 93 5.13.3 BARGAINING POWER OF BUYERS 93 5.13.4 BARGAINING POWER OF SUPPLIERS 93 5.13.5 INTENSITY OF COMPETITIVE RIVALRY 94 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 94 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 94 5.14.2 KEY BUYING CRITERIA 95 5.15 INVESTMENT & FUNDING SCENARIO 96 5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET 97   6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT 99 6.1 INTRODUCTION 100 6.2 ASSAY KITS & REAGENTS 100 6.2.1 TCR KITS 103 6.2.1.1 Human TCR kits 106 6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth 106 6.2.1.2 Mouse TCR kits 108 6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment 108 6.2.2 BCR KITS 110 6.2.2.1 Human BCR kits 113 6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake 113 6.2.2.2 Mouse BCR kits 115 6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth 115 6.2.3 OTHER ASSAY KITS & REAGENTS 118 6.3 INSTRUMENTS & SOFTWARE 120 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH 120 7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY 124 7.1 INTRODUCTION 125 7.2 SEQUENCING TECHNOLOGIES 125 7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES 128 7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth 128 7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES 130 7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth 130 7.3 LIBRARY PREPARATION TECHNOLOGIES 133 7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH 133 7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES 135 7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES 135   8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW 138 8.1 INTRODUCTION 139 8.2 SEQUENCING SERVICES 139 8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET 139 8.3 DATA ANALYSIS SERVICES 142 8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET 142 8.4 PRE-SEQUENCING SERVICES 144 8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH 144 9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION 147 9.1 INTRODUCTION 148 9.2 RESEARCH APPLICATIONS 148 9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET 148 9.3 DRUG DISCOVERY & DEVELOPMENT 151 9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH 151 9.4 CLINICAL DIAGNOSTICS 153 9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH 153 10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER 157 10.1 INTRODUCTION 158 10.2 ACADEMIC & RESEARCH INSTITUTES 158 10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET 158 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 161 10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH 161 10.4 OTHER END USERS 164 11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER 167 11.1 INTRODUCTION 168 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 168 11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH 168 11.3 ACADEMIC & RESEARCH INSTITUTES 171 11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH 171 11.4 OTHER END USERS 174   12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION 177 12.1 INTRODUCTION 178 12.2 NORTH AMERICA 178 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183 12.2.2 US 183 12.2.2.1 US to dominate North American market during forecast period 183 12.2.3 CANADA 187 12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth 187 12.3 EUROPE 191 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 191 12.3.2 GERMANY 196 12.3.2.1 Technological advancements in RNA sequencing to fuel market growth 196 12.3.3 UK 199 12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth 199 12.3.4 FRANCE 203 12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth 203 12.3.5 ITALY 207 12.3.5.1 High investments in genomic research to drive market 207 12.3.6 SPAIN 210 12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth 210 12.3.7 REST OF EUROPE 214 12.4 ASIA PACIFIC 217 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 222 12.4.2 CHINA 223 12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market 223 12.4.3 JAPAN 227 12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth 227 12.4.4 INDIA 231 12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth 231 12.4.5 SOUTH KOREA 234 12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth 234 12.4.6 AUSTRALIA 238 12.4.6.1 Increased research funding and favorable government initiatives to drive market 238 12.4.7 REST OF ASIA PACIFIC 241   12.5 LATIN AMERICA 245 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 249 12.5.2 BRAZIL 249 12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth 249 12.5.3 MEXICO 253 12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth 253 12.5.4 REST OF LATIN AMERICA 256 12.6 MIDDLE EAST 260 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 263 12.6.2 GCC COUNTRIES 264 12.6.2.1 Favorable government initiatives to drive drug development and clinical research 264 12.6.3 REST OF MIDDLE EAST 268 12.7 AFRICA 271 12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH 271 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 275 13 COMPETITIVE LANDSCAPE 276 13.1 INTRODUCTION 276 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022−2025 276 13.3 REVENUE ANALYSIS, 2022−2024 278 13.4 MARKET SHARE ANALYSIS, 2024 280 13.5 COMPANY VALUATION & FINANCIAL METRICS 283 13.5.1 COMPANY VALUATION 283 13.5.2 FINANCIAL METRICS 283 13.6 BRAND/PRODUCT COMPARISON 284 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 285 13.7.1 STARS 285 13.7.2 EMERGING LEADERS 285 13.7.3 PERVASIVE PLAYERS 285 13.7.4 PARTICIPANTS 285 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 287 13.7.5.1 Company footprint 287 13.7.5.2 Region footprint 287 13.7.5.3 Product and service footprint 288 13.7.5.4 Application footprint 289   13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 290 13.8.1 PROGRESSIVE COMPANIES 290 13.8.2 RESPONSIVE COMPANIES 290 13.8.3 DYNAMIC COMPANIES 290 13.8.4 STARTING BLOCKS 290 13.8.5 COMPETITIVE BENCHMARKING 292 13.8.5.1 Detailed list of key startups/SMEs 292 13.8.5.2 Competitive benchmarking of key startups/SMEs 293 13.9 COMPETITIVE SCENARIO 294 13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES 294 13.9.2 DEALS 295 13.9.3 EXPANSIONS 296 14 COMPANY PROFILES 297 14.1 KEY PLAYERS 297 14.1.1 ILLUMINA, INC. 297 14.1.1.1 Business overview 297 14.1.1.2 Products/Services/Solutions offered 298 14.1.1.3 Recent developments 301 14.1.1.3.1 Product launches/approvals/upgrades 301 14.1.1.3.2 Deals 302 14.1.1.3.3 Expansions 302 14.1.1.4 MnM view 303 14.1.1.4.1 Key strengths 303 14.1.1.4.2 Strategic choices 303 14.1.1.4.3 Weaknesses & competitive threats 303 14.1.2 THERMO FISHER SCIENTIFIC INC. 304 14.1.2.1 Business overview 304 14.1.2.2 Products/Services/Solutions offered 305 14.1.2.3 Recent developments 307 14.1.2.3.1 Product launches/approvals/upgrades 307 14.1.2.3.2 Deals 308 14.1.2.3.3 Expansions 308 14.1.2.4 MnM view 308 14.1.2.4.1 Key strengths 308 14.1.2.4.2 Strategic choices 308 14.1.2.4.3 Weaknesses & competitive threats 308   14.1.3 PACBIO 309 14.1.3.1 Business overview 309 14.1.3.2 Products/Services/Solutions offered 310 14.1.3.3 Recent developments 312 14.1.3.3.1 Product launches/approvals/upgrades 312 14.1.3.3.2 Deals 313 14.1.3.3.3 Expansions 314 14.1.3.4 MnM view 314 14.1.3.4.1 Key strengths 314 14.1.3.4.2 Strategic choices 314 14.1.3.4.3 Weaknesses & competitive threats 314 14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC 315 14.1.4.1 Business overview 315 14.1.4.2 Products/Services/Solutions offered 316 14.1.4.3 Recent developments 318 14.1.4.3.1 Product launches/approvals/upgrades 318 14.1.4.3.2 Deals 318 14.1.4.4 MnM view 319 14.1.4.4.1 Key strengths 319 14.1.4.4.2 Strategic choices 319 14.1.4.4.3 Weaknesses & competitive threats 319 14.1.5 10X GENOMICS 320 14.1.5.1 Business overview 320 14.1.5.2 Products/Services/Solutions offered 321 14.1.5.3 Recent developments 322 14.1.5.3.1 Product launches/approvals/upgrades 322 14.1.5.4 MnM view 323 14.1.5.4.1 Key strengths 323 14.1.5.4.2 Strategic choices 323 14.1.5.4.3 Weaknesses & competitive threats 323 14.1.6 QIAGEN 324 14.1.6.1 Business overview 324 14.1.6.2 Products/Services/Solutions offered 325 14.1.6.3 Recent developments 327 14.1.6.3.1 Product launches/approvals/upgrades 327 14.1.6.3.2 Deals 328 14.1.6.3.3 Expansions 328   14.1.7 AGILENT TECHNOLOGIES 329 14.1.7.1 Business overview 329 14.1.7.2 Products/Services/Solutions offered 330 14.1.7.3 Recent developments 331 14.1.7.3.1 Deals 331 14.1.7.3.2 Expansions 331 14.1.8 DANAHER CORPORATION 332 14.1.8.1 Business overview 332 14.1.8.2 Products/Services/Solutions offered 333 14.1.8.3 Recent developments 334 14.1.8.3.1 Deals 334 14.1.9 TAKARA BIO INC. 336 14.1.9.1 Business overview 336 14.1.9.2 Products/Services/Solutions offered 337 14.1.9.3 Recent developments 339 14.1.9.3.1 Deals 339 14.1.10 ADAPTIVE BIOTECHNOLOGIES 340 14.1.10.1 Business overview 340 14.1.10.2 Products/Services/Solutions offered 341 14.1.11 BGI GROUP 342 14.1.11.1 Business overview 342 14.1.11.2 Products/Services/Solutions offered 342 14.1.11.3 Recent developments 344 14.1.11.3.1 Product launches/approvals/upgrades 344 14.1.11.3.2 Deals 345 14.1.11.3.3 Other developments 346 14.1.12 TECAN TRADING AG 347 14.1.12.1 Business overview 347 14.1.12.2 Products/Services/Solutions offered 348 14.1.12.3 Recent developments 349 14.1.12.3.1 Deals 349 14.1.13 AZENTA US INC. 350 14.1.13.1 Business overview 350 14.1.13.2 Products/Services/Solutions offered 351 14.1.14 PERSONALIS, INC. 352 14.1.14.1 Business overview 352 14.1.14.2 Products/Services/Solutions offered 353 14.1.14.3 Recent developments 354 14.1.14.3.1 Deals 354 14.1.14.3.2 Other developments 354   14.1.15 CREATIVE BIOLABS 355 14.1.15.1 Business overview 355 14.1.15.2 Products/Services/Solutions offered 355 14.2 OTHER PLAYERS 356 14.2.1 CELEMICS, INC. 356 14.2.2 CELLCARTA 356 14.2.3 IREPERTOIRE, INC. 357 14.2.4 NEW ENGLAND BIOLABS 358 14.2.5 CERBA RESEARCH 359 14.2.6 CEGAT GMBH 359 14.2.7 ELEMENT BIOSCIENCES 360 14.2.8 SEQALIS 360 14.2.9 SYNBIO TECHNOLOGIES 361 14.2.10 MEDGENOME 361 14.2.11 ENPICOM 362 15 APPENDIX 363 15.1 DISCUSSION GUIDE 363 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367 15.3 CUSTOMIZATION OPTIONS 369 15.4 RELATED REPORTS 369 15.5 AUTHOR DETAILS 370
圖表清單 List of Tables & Figures
TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS 40 TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 50 TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS 53 TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS 63 TABLE 5 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 69 TABLE 6 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD) 71 TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS 76 TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS 76 TABLE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS 77 TABLE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: REGULATORY BODIES 77 TABLE 11 INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025 82 TABLE 12 IMPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD) 83 TABLE 13 EXPORT DATA FOR HS CODE 3822, BY REGION, 2020−2024 (USD) 84 TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 85 TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86 TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 19 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES 93 TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 94 TABLE 21 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET) 95 TABLE 22 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET) 96 TABLE 23 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 100 TABLE 24 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 101 TABLE 25 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 26 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 27 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 28 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 29 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 30 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023–2030 (USD MILLION) 103 TABLE 31 TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 103 TABLE 32 TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 33 NORTH AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 34 EUROPE: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 35 ASIA PACIFIC: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 36 LATIN AMERICA: TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 105 TABLE 37 MIDDLE EAST: TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 38 HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 39 NORTH AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 106 TABLE 40 EUROPE: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 41 ASIA PACIFIC: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 42 LATIN AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 107 TABLE 43 MIDDLE EAST: HUMAN TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 44 MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 45 NORTH AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 46 EUROPE: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 47 ASIA PACIFIC: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 48 LATIN AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 49 MIDDLE EAST: MOUSE TCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 50 BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 111 TABLE 51 BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 52 NORTH AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111 TABLE 53 EUROPE: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 54 ASIA PACIFIC: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 55 LATIN AMERICA: BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 56 MIDDLE EAST: BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 57 HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 58 NORTH AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 59 EUROPE: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 60 ASIA PACIFIC: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 61 LATIN AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 62 MIDDLE EAST: HUMAN BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 63 MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 64 NORTH AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 65 EUROPE: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 66 ASIA PACIFIC: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 67 LATIN AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 68 MIDDLE EAST: MOUSE BCR KITS MARKET, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 69 OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 70 NORTH AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 71 EUROPE: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 72 ASIA PACIFIC: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 73 LATIN AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 74 MIDDLE EAST: OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 75 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 76 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 77 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 78 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 79 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 80 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 81 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 125 TABLE 82 SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 125 TABLE 83 SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 84 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 85 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 86 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 87 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 88 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 89 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 90 NORTH AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 91 EUROPE: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 92 ASIA PACIFIC: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 93 LATIN AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 94 MIDDLE EAST: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 95 SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 131 TABLE 96 NORTH AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 97 EUROPE: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 98 ASIA PACIFIC: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 99 LATIN AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 100 MIDDLE EAST: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 101 LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 133 TABLE 102 NORTH AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 103 EUROPE: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 104 ASIA PACIFIC: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 105 LATIN AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 135 TABLE 106 MIDDLE EAST: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 135 TABLE 107 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 136 TABLE 108 NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 109 EUROPE: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136 TABLE 110 ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 111 LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 112 MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 113 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 139 TABLE 114 SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 140 TABLE 115 NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 116 EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 117 ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 118 LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 119 MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 141 TABLE 120 DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 121 NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 122 EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 123 ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 124 LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 125 MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 126 PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 144 TABLE 127 NORTH AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 128 EUROPE: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 129 ASIA PACIFIC: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 130 LATIN AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 131 MIDDLE EAST: PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 146 TABLE 132 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 148 TABLE 133 IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 149 TABLE 134 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 135 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 136 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 137 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 138 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 139 IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 151 TABLE 140 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 141 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 142 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 143 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 144 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 145 IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 154 TABLE 146 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 147 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 148 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 149 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 150 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 151 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 158 TABLE 152 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 159 TABLE 153 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 154 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 155 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 156 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 161 TABLE 157 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 158 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 162 TABLE 159 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 160 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 161 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 162 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 163 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 164 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 165 TABLE 165 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 166 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 167 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 168 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 169 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 166 TABLE 170 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 168 TABLE 171 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 169 TABLE 172 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 173 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 174 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 175 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 176 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 171 TABLE 177 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 172 TABLE 178 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 179 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 180 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 181 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 182 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 183 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 174 TABLE 184 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 185 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 186 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 187 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 188 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 189 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION) 178 TABLE 190 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 191 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 180 TABLE 192 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 193 NORTH AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 194 NORTH AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 195 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 181 TABLE 196 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 181 TABLE 197 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 198 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 182 TABLE 199 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 200 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 182 TABLE 201 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 183 TABLE 202 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 184 TABLE 203 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 204 US: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 205 US: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 206 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 185 TABLE 207 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 185 TABLE 208 US: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 186 TABLE 209 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 186 TABLE 210 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 211 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 187 TABLE 212 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 187 TABLE 213 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 214 CANADA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 215 CANADA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 216 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 189 TABLE 217 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 189 TABLE 218 CANADA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 219 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 190 TABLE 220 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 221 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 222 EUROPE: KEY MACROECONOMIC INDICATORS 192 TABLE 223 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 224 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 193 TABLE 225 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 226 EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 227 EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 193 TABLE 228 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 194 TABLE 229 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 194 TABLE 230 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 194 TABLE 231 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 195 TABLE 232 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 233 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 195 TABLE 234 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 196 TABLE 235 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 236 GERMANY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 237 GERMANY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 197 TABLE 238 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 197 TABLE 239 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 198 TABLE 240 GERMANY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 241 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 198 TABLE 242 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 243 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 199 TABLE 244 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 200 TABLE 245 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 246 UK: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 247 UK: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 248 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 201 TABLE 249 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 201 TABLE 250 UK: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 202 TABLE 251 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 202 TABLE 252 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 202 TABLE 253 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 203 TABLE 254 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 204 TABLE 255 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 256 FRANCE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 257 FRANCE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 204 TABLE 258 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 205 TABLE 259 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 205 TABLE 260 FRANCE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 205 TABLE 261 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 206 TABLE 262 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 263 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 264 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 207 TABLE 265 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 207 TABLE 266 ITALY: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 267 ITALY: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 208 TABLE 268 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 208 TABLE 269 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 209 TABLE 270 ITALY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 209 TABLE 271 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 272 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 273 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 274 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 211 TABLE 275 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 276 SPAIN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 277 SPAIN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 211 TABLE 278 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 212 TABLE 279 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 212 TABLE 280 SPAIN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 212 TABLE 281 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 282 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 283 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 213 TABLE 284 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 214 TABLE 285 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 214 TABLE 286 REST OF EUROPE: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 287 REST OF EUROPE: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 215 TABLE 288 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 215 TABLE 289 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 216 TABLE 290 REST OF EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 216 TABLE 291 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 216 TABLE 292 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER,2023–2030 (USD MILLION) 217 TABLE 293 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 217 TABLE 294 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 219 TABLE 295 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 219 TABLE 296 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 219 TABLE 297 ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 298 ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 220 TABLE 299 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 220 TABLE 300 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 221 TABLE 301 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 221 TABLE 302 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 221 TABLE 303 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 304 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 222 TABLE 305 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 223 TABLE 306 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 224 TABLE 307 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 308 CHINA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 309 CHINA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 224 TABLE 310 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 225 TABLE 311 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 225 TABLE 312 CHINA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 225 TABLE 313 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 314 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 315 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 226 TABLE 316 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 227 TABLE 317 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 318 JAPAN: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 319 JAPAN: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 228 TABLE 320 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 229 TABLE 321 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 229 TABLE 322 JAPAN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 229 TABLE 323 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 324 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 325 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 230 TABLE 326 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 231 TABLE 327 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 231 TABLE 328 INDIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 329 INDIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 232 TABLE 330 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 232 TABLE 331 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 233 TABLE 332 INDIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 233 TABLE 333 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 334 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 335 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 234 TABLE 336 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 235 TABLE 337 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 338 SOUTH KOREA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 339 SOUTH KOREA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 235 TABLE 340 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 236 TABLE 341 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 236 TABLE 342 SOUTH KOREA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 236 TABLE 343 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 344 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 237 TABLE 345 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 237 TABLE 346 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 238 TABLE 347 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 238 TABLE 348 AUSTRALIA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 349 AUSTRALIA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 239 TABLE 350 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 239 TABLE 351 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 240 TABLE 352 AUSTRALIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 240 TABLE 353 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 240 TABLE 354 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 355 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 241 TABLE 356 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 242 TABLE 357 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 358 REST OF ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 359 REST OF ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 242 TABLE 360 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 243 TABLE 361 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 243 TABLE 362 REST OF ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 243 TABLE 363 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 244 TABLE 364 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 365 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 366 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245 TABLE 367 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 245 TABLE 368 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 369 LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 370 LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 246 TABLE 371 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 247 TABLE 372 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 247 TABLE 373 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 247 TABLE 374 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 248 TABLE 375 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 376 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 377 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 249 TABLE 378 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 250 TABLE 379 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 380 BRAZIL: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 381 BRAZIL: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 250 TABLE 382 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 251 TABLE 383 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 251 TABLE 384 BRAZIL: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 251 TABLE 385 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 386 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 252 TABLE 387 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 252 TABLE 388 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 253 TABLE 389 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 253 TABLE 390 MEXICO: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 391 MEXICO: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 254 TABLE 392 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 254 TABLE 393 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 255 TABLE 394 MEXICO: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 255 TABLE 395 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 396 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 397 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 256 TABLE 398 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 257 TABLE 399 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 400 REST OF LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 401 REST OF LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 257 TABLE 402 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 258 TABLE 403 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 258 TABLE 404 REST OF LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 258 TABLE 405 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 406 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 259 TABLE 407 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 259 TABLE 408 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023–2030 (USD MILLION) 260 TABLE 409 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 260 TABLE 410 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 260 TABLE 411 MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 412 MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 261 TABLE 413 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 261 TABLE 414 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 262 TABLE 415 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 262 TABLE 416 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 262 TABLE 417 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 418 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 263 TABLE 419 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 264 TABLE 420 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 264 TABLE 421 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 422 GCC COUNTRIES: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 423 GCC COUNTRIES: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 265 TABLE 424 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 266 TABLE 425 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266 TABLE 426 GCC COUNTRIES: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 266 TABLE 427 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 428 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 267 TABLE 429 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 267 TABLE 430 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 268 TABLE 431 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 268 TABLE 432 REST OF MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 433 REST OF MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 269 TABLE 434 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 269 TABLE 435 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 270 TABLE 436 REST OF MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 270 TABLE 437 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 270 TABLE 438 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 271 TABLE 439 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 271 TABLE 440 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 272 TABLE 441 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 442 AFRICA: TCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 272 TABLE 443 AFRICA: BCR KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 273 TABLE 444 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023–2030 (USD MILLION) 273 TABLE 445 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 273 TABLE 446 AFRICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023–2030 (USD MILLION) 274 TABLE 447 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 448 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION) 274 TABLE 449 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 275 TABLE 450 AFRICA: KEY MACROECONOMIC INDICATORS 275 TABLE 451 IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022−2025 276 TABLE 452 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: DEGREE OF COMPETITION, 2024 281 TABLE 453 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET: DEGREE OF COMPETITION, 2024 282 TABLE 454 IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT 287 TABLE 455 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT 288 TABLE 456 IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT 289 TABLE 457 IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 292 TABLE 458 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 293 TABLE 459 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 294 TABLE 460 IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS, JANUARY 2022–MARCH 2025 295 TABLE 461 IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025 296 TABLE 462 ILLUMINA, INC.: COMPANY OVERVIEW 297 TABLE 463 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 298 TABLE 464 ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 301 TABLE 465 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025 302 TABLE 466 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 302 TABLE 467 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 304 TABLE 468 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 305 TABLE 469 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 307 TABLE 470 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025 308 TABLE 471 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 308 TABLE 472 PACBIO: COMPANY OVERVIEW 309 TABLE 473 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED 310 TABLE 474 PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 312 TABLE 475 PACBIO: DEALS, JANUARY 2022–MARCH 2025 313 TABLE 476 PACBIO: EXPANSIONS, JANUARY 2022–MARCH 2025 314 TABLE 477 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 315 TABLE 478 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED 316 TABLE 479 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 318 TABLE 480 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022–MARCH 2025 318 TABLE 481 10X GENOMICS: COMPANY OVERVIEW 320 TABLE 482 10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 321 TABLE 483 10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 322 TABLE 484 QIAGEN: COMPANY OVERVIEW 324 TABLE 485 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 325 TABLE 486 QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 327 TABLE 487 QIAGEN: DEALS, JANUARY 2022–MARCH 2025 328 TABLE 488 QIAGEN: EXPANSIONS, JANUARY 2022–MARCH 2025 328 TABLE 489 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 329 TABLE 490 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 330 TABLE 491 AGILENT TECHNOLOGIES: DEALS, JANUARY 2022–MARCH 2025 331 TABLE 492 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022–MARCH 2025 331 TABLE 493 DANAHER CORPORATION: COMPANY OVERVIEW 332 TABLE 494 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 333 TABLE 495 DANAHER CORPORATION: DEALS, JANUARY 2022–MARCH 2025 334 TABLE 496 TAKARA BIO INC.: COMPANY OVERVIEW 336 TABLE 497 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 337 TABLE 498 TAKARA BIO INC.: DEALS, JANUARY 2022–MARCH 2025 339 TABLE 499 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW 340 TABLE 500 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED 341 TABLE 501 BGI GROUP: COMPANY OVERVIEW 342 TABLE 502 BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED 342 TABLE 503 BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025 344 TABLE 504 BGI GROUP: DEALS, JANUARY 2022–MARCH 2025 345 TABLE 505 BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 346 TABLE 506 TECAN TRADING AG: COMPANY OVERVIEW 347 TABLE 507 TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED 348 TABLE 508 TECAN TRADING AG: DEALS, JANUARY 2022–MARCH 2025 349 TABLE 509 AZENTA US INC.: COMPANY OVERVIEW 350 TABLE 510 AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 351 TABLE 511 PERSONALIS, INC.: COMPANY OVERVIEW 352 TABLE 512 PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 353 TABLE 513 PERSONALIS, INC.: DEALS, JANUARY 2022–MARCH 2025 354 TABLE 514 PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 354 TABLE 515 CREATIVE BIOLABS: COMPANY OVERVIEW 355 TABLE 516 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 355 TABLE 517 CELEMICS, INC.: COMPANY OVERVIEW 356 TABLE 518 CELLCARTA: COMPANY OVERVIEW 356 TABLE 519 IREPERTOIRE, INC.: COMPANY OVERVIEW 357 TABLE 520 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 358   TABLE 521 CERBA RESEARCH: COMPANY OVERVIEW 359 TABLE 522 CEGAT GMBH: COMPANY OVERVIEW 359 TABLE 523 ELEMENT BIOSCIENCES: COMPANY OVERVIEW 360 TABLE 524 SEQALIS: COMPANY OVERVIEW 360 TABLE 525 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW 361 TABLE 526 MEDGENOME: COMPANY OVERVIEW 361 TABLE 527 ENPICOM: COMPANY OVERVIEW 362 FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD 39 FIGURE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: YEARS CONSIDERED 41 FIGURE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN 42 FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: BREAKDOWN OF PRIMARIES 44 FIGURE 5 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024) 45 FIGURE 6 GLOBAL PRODUCTS MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 46 FIGURE 7 GLOBAL SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024) 46 FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE VALIDATION FROM PRIMARY SOURCES 48 FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TOP-DOWN APPROACH 48 FIGURE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: CAGR PROJECTIONS 50 FIGURE 11 DATA TRIANGULATION METHODOLOGY 51 FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 54 FIGURE 13 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 55 FIGURE 14 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION) 55 FIGURE 15 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 56 FIGURE 16 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 56 FIGURE 17 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57 FIGURE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT 57 FIGURE 19 INCREASING ADOPTION OF PERSONALIZED MEDICINES AND RISING FOCUS ON GENOMIC RESEARCH TO DRIVE MARKET 59 FIGURE 20 US AND ASSAY KITS & REAGENTS DOMINATED NORTH AMERICAN MARKET IN 2024 60 FIGURE 21 SEQUENCING TECHNOLOGIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030 60 FIGURE 22 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND LARGEST END USER MARKET SHARE IN 2025 61 FIGURE 23 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 61 FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62 FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 68 FIGURE 26 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER (2024) 70 FIGURE 27 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD) 71 FIGURE 28 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS 73 FIGURE 29 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS 74 FIGURE 30 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS 75 FIGURE 31 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015–DECEMBER 2024) 81 FIGURE 32 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS 92 FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 94 FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET) 95 FIGURE 35 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET) 95 FIGURE 36 FUNDING AND NUMBER OF PROJECTS AND SUB-PROJECTS BY NATIONAL INSTITUTES OF HEALTH, 2021–2025 97 FIGURE 37 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET 98 FIGURE 38 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT 179 FIGURE 39 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT 218 FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022−2024) 278 FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022−2024) 279 FIGURE 42 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024 280 FIGURE 43 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024 281 FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 283 FIGURE 45 EV/EBITDA OF KEY PLAYERS 283 FIGURE 46 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 284 FIGURE 47 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 286 FIGURE 48 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT 287 FIGURE 49 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 291 FIGURE 50 ILLUMINA, INC.: COMPANY SNAPSHOT 298 FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 305 FIGURE 52 PACBIO: COMPANY SNAPSHOT 310 FIGURE 53 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT 316 FIGURE 54 10X GENOMICS: COMPANY SNAPSHOT 321 FIGURE 55 QIAGEN: COMPANY SNAPSHOT 325 FIGURE 56 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT 330 FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT 333 FIGURE 58 TAKARA BIO INC.: COMPANY SNAPSHOT 337 FIGURE 59 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT 340 FIGURE 60 TECAN TRADING AG: COMPANY SNAPSHOT 348 FIGURE 61 AZENTA US INC.: COMPANY SNAPSHOT 351 FIGURE 62 PERSONALIS, INC.: COMPANY SNAPSHOT 353

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們